• Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (Posted Jan. 30, 2009)
  From HIV i-Base
• Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (Posted Nov. 26, 2008)
  From Project Inform
• Study Shows People Can Safely Switch to Atripla (Posted Nov. 26, 2008)
  From Project Inform
• Merck's Antiretroviral Isentress More Efficient in Suppressing HIV Among Untreated Patients (Posted Oct. 28, 2008)
  From Henry J. Kaiser Family Foundation
• Antiretroviral Treatment Should Start Earlier, Study Says (Posted Oct. 27, 2008)
  From Henry J. Kaiser Family Foundation
• Conference Highlights: New Studies on New (and Not Quite as New) HIV Meds (Posted Oct. 27, 2008)
  From Lexiva to Reyataz and from Prezista to Isentress, several clinical trials were presented at ICAAC/IDSA 2008 that showed promising results for our more recently approved HIV medications. Eric Daar, M.D., gives us the lowdown on these studies and how they may change the HIV treatment landscape.
  

  Read or listen (7 min.):

  From TheBodyPRO.com
• Studies: Newer HIV Drugs More Tolerable for Many (Posted Oct. 27, 2008)
  From U.S. Centers for Disease Control and Prevention
• 96-Week ARTEMIS Data Indicate Darunavir Is Superior to Lopinavir in Naive Patients (Posted Oct. 26, 2008)
  Following 48-week data that proved darunavir's non-inferiority to lopinavir, these new, even more encouraging 96-week data appear likely to solidify the drug's role in first-line therapy. (An interview with Tony Mills, M.D.)
  

  Read or listen (4 min.):

  From TheBodyPRO.com
• Crafting First-Line Regimens: So Easy a General Practitioner Could Do It? (Posted Oct. 26, 2008)
  We may have more antiretrovirals to choose from than ever before, but selecting an initial HAART regimen today is often a choice between just two regimens, a new study indicates. The findings suggest it may be realistic for primary care physicians and general practitioners to shoulder more of the HIV care burden. (An interview with James McKinnell, M.D.)
  

  Read or listen (12 min.):

  From TheBodyPRO.com
• HEAT: Virologic Failure Rates Similar (and Low), Emerging Resistance Uncommon on Abacavir/Lamivudine vs. Tenofovir/Emtricitabine (Posted Oct. 26, 2008)
  The similarities between these two first-line nucleoside backbones is reiterated in a new examination of virologic failure data from the 96-week results of the HEAT study. (An interview with Benjamin Young, M.D., Ph.D.)
  

  Read or listen (10 min.):

  From TheBodyPRO.com
• Large Study Supports Earlier Treatment (Posted Oct. 26, 2008)
  From Project Inform
• RDEA Study Supports Further Development of New NNRTI (Posted Oct. 26, 2008)
  From Project Inform
• Results From Elvucitabine Study Unimpressive (Posted Oct. 26, 2008)
  From Project Inform
• Starting HAART: Should 500 Become the New 350? (Posted Oct. 26, 2008)
  Mari Kitahata, M.D., and Daniel Kuritzkes, M.D., discuss a 5,926-patient trial that found a 74% higher mortality risk among those who deferred HAART until their CD4 dropped below 350 rather than initiating when their CD4 was between 351 and 500. Dr. Kuritzkes also touches on new developments in HIV drug resistance.
  

  Read or listen (35 min.):

  From TheBodyPRO.com
• Study Data Explain Raltegravir's Excellent Resistance Profile (Posted Oct. 26)
  From Project Inform
• Study May Point Way Forward for Bevirimat (Posted Oct. 26, 2008)
  From Project Inform
• Study Shows Better Results From Vicriviroc When New Trofile Test Is Used (Posted Oct. 26)
  From Project Inform
• Study Supports Use of Isentress for First-Line Treatment (Posted Oct. 26, 2008)
  From Project Inform
• Switching From Combivir to Truvada Keeps HIV Undetectable, Improves Blood Fats, But Fails to Improve Limb Fat (Posted Oct. 26, 2008)
  From Project Inform
• Trend Toward Fewer AIDS-Defining Conditions Among Patients Receiving Raltegravir vs. Placebo (Posted Oct. 26, 2008)
  A new examination of 48-week BENCHMRK data found a nearly twofold reduction in AIDS-defining events among patients on raltegravir, but the findings failed to reach statistical significance. Intriguingly, greater resistance did not appear to be a predictor of AIDS-defining events. (An interview with Joseph Eron Jr., M.D.)
  

  Read or listen (7 min.):

  From TheBodyPRO.com

The Body PRO's coverage of The 48th Annual ICAAC/IDSA 46th Annual Meeting will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on The 48th Annual ICAAC/IDSA 46th Annual Meeting, please visit the conference's Web site. You may also view the conference program online.